Updates on germline predisposition in pediatric hematologic malignancies: What is the role of flow cytometry?
Cytometry Part B: Clinical Cytometry · 2024
DOI: 10.1002/cyto.b.22192 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2024. Verfasst von Nadine Demko und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA. Hauptthemen laut MEDLINE: Flow Cytometry, Hematologic Neoplasms, Germ-Line Mutation, Immunophenotyping. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben.
Abstract (Originalsprache)
Hematologic neoplasms with germline predisposition have been increasingly recognized as a distinct category of tumors over the last few years. As such, this category was added to the World Health Organization (WHO) 4th edition as well as maintained in the WHO 5th edition and International Consensus Classification (ICC) 2022 classification systems. In practice, these tumors require a high index of suspicion and confirmation by molecular testing. Flow cytometry is a cost‐effective diagnostic tool that is routinely performed on peripheral blood and bone marrow samples. In this review, we sought to summarize the current body of research correlating flow cytometric immunophenotype to assess its utility in diagnosis of and clinical decision making in germline hematologic neoplasms. We also illustrate these findings using cases mostly from our own institution. We review some of the more commonly mutated genes, including CEBPA, DDX41, RUNX1, ANKRD26, GATA2 , Fanconi anemia, Noonan syndrome, and Down syndrome. We highlight that flow cytometry may have a role in the diagnosis ( GATA2 , Down syndrome) and screening ( CEBPA ) of some germline predisposition syndromes, although appears to show nonspecific findings in others ( DDX41, RUNX1 ). In many of the others, such as ANKRD26 , Fanconi anemia, and Noonan syndrome, further studies are needed to better understand whether specific flow cytometric patterns are observed. Ultimately, we conclude that further studies such as large case series and organized data pipelines are needed in most germline settings to better understand the flow cytometric immunophenotype of these neoplasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.
- Department of Pathology, McGill University, Montréal, Québec, Canada.
ORCID-Profile: Nadine Demko
Zitieren
APA
Demko, N., & Geyer, J. T. (2024). Updates on germline predisposition in pediatric hematologic malignancies: What is the role of flow cytometry?. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22192
Vancouver
Demko N, Geyer JT. Updates on germline predisposition in pediatric hematologic malignancies: What is the role of flow cytometry?. Cytometry Part B: Clinical Cytometry. 2024. doi:10.1002/cyto.b.22192
BibTeX
@article{Demko2024,
author = {Demko, Nadine and Geyer, Julia T},
title = {Updates on germline predisposition in pediatric hematologic malignancies: What is the role of flow cytometry?},
journal = {Cytometry Part B: Clinical Cytometry},
year = {2024},
doi = {10.1002/cyto.b.22192}
}
EUVIMED